Comparative Effectiveness of 18F-FDG PET/CT Versus Whole-Body MRI for Detection of Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1
Authors:
- Thorsten DerlinTDThorsten Derlin
- Katharina TornquistKTKatharina Tornquist
- Silvia MünsterSMSilvia Münster
- Ivayla ApostolovaIAIvayla Apostolova
- Christian HagelCHChristian Hagel
- Reinhard E. FriedrichRFReinhard E. Friedrich
- Ulrike WedegärtnerUWUlrike Wedegärtner
- Victor F. MautnerVMVictor F. Mautner
- 1 January 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 38 (1) , e19-e25
Abstract
The aim of this study was to compare the diagnostic performance of ¹⁸F-fluorodeoxyglucose (FDG) PET/CT and whole-body MRI for the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1, and to evaluate a panel of imaging-based criteria serving that purpose. Thirty-one patients were examined by whole-body MRI and ¹⁸F-FDG PET/CT. A panel of imaging-based criteria including tumor region, size, shape, margin definition, contrast enhancement, heterogeneity before and after contrast, intratumoral lobulation, target sign, and mean and maximum standardized uptake values (SUVs) were evaluated. A SUVmax cut-off value of 3.5 was used for lesion analysis. Histopathologic evaluation and/or clinical follow-up served as the reference standard. ¹⁸F-FDG PET/CT had a sensitivity of 100%, whereas MRI had a sensitivity of 66.7%. On PET/CT, tumor size (P<0.005), SUVmax (P<0.0001), SUVmean (P<0.0001), and tracer uptake heterogeneity (P=0.002) were significantly associated with MPNSTs. On MRI, intratumoral lobulation (P<0.02), ill-defined margins (P=0.007), and irregular enhancement on T1-weighted imaging (P<0.001) were significantly associated with MPNSTs. Both PET/CT and whole-body MRI may distinguish benign and malignant PNSTs, but PET/CT has higher sensitivity for that purpose. Imaging-based criteria for identification of MPNSTs on both modalities were identified. False-positive results, requiring biopsy or clinical follow-up, may be reduced by using a combination of MRI and PET derived markers, but only at the price of reduced sensitivity.Keywords
This publication has 21 references indexed in Scilit:
- Utilization of positron emission tomography in the management of patients with sarcomaCurrent Opinion in Oncology, 2009
- [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1European Journal of Nuclear Medicine and Molecular Imaging, 2009
- Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1Neuro-Oncology, 2008
- [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical studyAnnals of Oncology, 2007
- MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1Neuroradiology, 2006
- Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Prevalence of Neurofibromatosis 1 in German Children at Elementary School EnrollmentArchives of Dermatology, 2005
- Malignant peripheral nerve sheath tumours in neurofibromatosis 1Journal of Medical Genetics, 2002
- Malignant peripheral nerve sheath tumor: analysis of treatment outcomeInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1998
- Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 casesCancer, 1986